Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752 is registered in ClinicalTrials.gov with VA Greater Los Angeles Healthcare System as lead sponsor.

NCT NCT02104752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02104752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Lead sponsor
VA Greater Los Angeles Healthcare System
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2014
Completion date
October 31, 2017
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognition, psychosis, schizophrenia